Positive Outlook for Taysha Gene Therapies: Expedited FDA Alignment and Strong Financial Position Support Buy Rating

Analyst Gil Blum from Needham reiterated a Buy rating on Taysha Gene Therapies (TSHA – Research Report) and keeping the price target at $6.00.

Gil Blum has given his Buy rating due to a combination of factors that indicate a positive outlook for Taysha Gene Therapies. The company has achieved alignment with the FDA on its pivotal study design for TSHA-102, which eliminates the need for an end of phase meeting. This development is expected to expedite the process by approximately one quarter, reducing regulatory uncertainty and suggesting that Taysha has a strong data package to support further development.
Additionally, Taysha’s financial position is robust, with a cash reserve of $117 million that is projected to sustain operations until the fourth quarter of 2026. The anticipated clinical updates, including natural history data and study design details, are expected to align with clinical milestones and demonstrate dose-dependence, further de-risking the investment. These factors collectively underpin the Buy rating and the $6 target price set by Gil Blum.

According to TipRanks, Blum is an analyst with an average return of -13.7% and a 30.43% success rate. Blum covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Autolus Therapeutics, and Immunocore Holdings.

In another report released on May 1, Piper Sandler also initiated coverage with a Buy rating on the stock with a $9.00 price target.